Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

65.63 +1.37 (+2.13%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc ADR

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
59 60 Next >
AstraZeneca's Blood Clot Treatment Hits Primary Goal In Rare Blood Disorder Trial
Via Benzinga
AstraZeneca Partners with Jeff Bridges, Kumail Nanjiani, and Emily V. Gordon to Educate the Immunocompromised Community about Added Protection Against COVID-19
From AstraZeneca
Via Business Wire
Top Financial Stories Tuesday, September 13: Elon Musk's Takeover Set To Get Twitter Shareholder Approval, Intel Slashes Mobileye IPO Valuation, Goldman Sachs To Layoff About 500 Jobs And More...
Wall Street Journal 
Via Benzinga
US Judge Dismisses Shareholder Lawsuit Over AstraZeneca's COVID-19 Vaccine Disclosures: Report
Via Benzinga
IMFINZI® (durvalumab) plus chemotherapy further improved overall survival benefit in advanced biliary tract cancer in the TOPAZ-1 Phase III trial, reducing the risk of death by 24% in additional follow-up
From AstraZeneca
Via Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2-mutant Metastatic Non-small Cell Lung Cancer
From AstraZeneca
Via Business Wire
IMFINZI® (durvalumab) and tremelimumab with chemotherapy demonstrated sustained survival benefit in metastatic non-small cell lung cancer, nearly doubling the number of patients alive after three years vs. chemotherapy
From AstraZeneca
Via Business Wire
TAGRISSO® (osimertinib) demonstrated 5.5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated lung cancer
From AstraZeneca
Via Business Wire
Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary
Via Benzinga
AstraZeneca-Merck's Lynparza Treatment Shows Long-Term Survival In Ovarian Cancer
Via Benzinga
LYNPARZA® (olaparib) in Combination with Bevacizumab, and as a Monotherapy, Demonstrates Clinically Meaningful Survival Benefit in 1st-Line Advanced Ovarian Cancer Across Two Phase III Trials
From AstraZeneca
Via Business Wire
Sanofi-GSK COVID-19 Vaccine May See European Approval Soon: Report
Via Benzinga
AstraZeneca Imfinzi Combo Scores FDA Approval As First Immunotherapy Regimen For Biliary Tract Cancer
Via Benzinga
IMFINZI® (durvalumab) Plus Chemotherapy Approved in the US as the First Immunotherapy Regimen for Patients with Advanced Biliary Tract Cancer
From AstraZeneca
Via Business Wire
White House May Ask For $25B Emergency Funding For COVID-19, Monkeypox
Via Benzinga
Here's How Much $1000 Invested In AstraZeneca 5 Years Ago Would Be Worth Today
AstraZeneca (NASDAQ:AZN) has outperformed the market over the past 5 years by 5.5% on an annualized basis producing an average annual return of 15.24%. Currently, AstraZeneca has a market... 
Via Benzinga
AstraZeneca Scores Its First Global Approval For Antibody Evusheld As COVID-19 Treatment
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 29, 2022
Upgrades 
Via Benzinga
Valneva Posts Additional Encouraging Data From COVID-19 Booster Trial
Via Benzinga
AstraZeneca Touts Positive Farxiga Data, Seeks Label Expansion In Heart Failure
AstraZeneca Plc (NASDAQ: AZN) laid out the details of the Farxiga's performance in another heart failure patient population at the European Society of Cardiology Congress. 
Via Benzinga
Week In Review: China And The US May Settle De-Listing/Accounting Impasse
China and the US are close to solving the accounting rules crisis that threatens to de-list 261 China companies from US exchanges. The list of affected biopharma companies includes BeiGene, Legend Bio,... 
Via Talk Markets
New data show FARXIGA significantly lowers the risk of cardiovascular death in patients with heart failure
From AstraZeneca
Via Business Wire
FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial
From AstraZeneca
Via Business Wire
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Back-To-Back Three Japanese Approvals For AstraZeneca's Rare Disease Treatments
Via Benzinga
AstraZeneca's CEO Says There Are No COVID Regrets, Looks For Oncology Acquisitions
In a Reuters report, AstraZeneca Plc's (NASDAQ: 
Via Benzinga
AstraZeneca aims to transform cancer outcomes with new data across industry-leading portfolio at ESMO 2022
From AstraZeneca
Via Business Wire
Sorrento Shares Pop After Interim Data From Lung Cancer Trial
Sorrento Therapeutics Inc (NASDAQ: SRNE) announced positive results from a pivotal study of Abivertinib on 209 response evaluable, heavily pretreated NSCLC patients by an IRC assessment with matured... 
Via Benzinga
Amgen Touts Positive Data From Soliris-Based Biosimilar For Rare Blood Disorder
Via Benzinga
Face Of US COVID-19 Response, Dr Anthony Fauci To Retire In December
  
Via Benzinga
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
59 60 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.